Physician profile
Ziyad Peer
NPI 1265998611
$88,871.72
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,613 · 2022: $30K · 2023: $33K · 2024: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $13K · Travel and Lodging: $12K · Consulting Fee: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,284.00 |
| Food and Beverage | $12,668.46 |
| Travel and Lodging | $12,415.34 |
| Consulting Fee | $11,676.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $53,567.10 | 2021-2024 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Atricure, INC. | $19,206.36 | 2021-2024 | |
| Boston Scientific Corporation | $7,271.70 | 2021-2024 | Watchman Access System, Watchman Flx |
| Abbott Laboratories | $4,724.80 | 2021-2024 | Jot Dx, Aveir, Gallant |
| Biosense Webster, INC. | $1,741.38 | 2021-2024 | Carto 3 |
| Impulse Dynamics (USA) INC. | $798.87 | 2021-2024 | Optimizer, Optimizer |
| Amgen INC. | $424.27 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $340.76 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $312.85 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $93.89 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $79.03 | 2022-2024 | Wainua |
| Pfizer INC. | $77.24 | 2022-2024 | |
| Cvrx, INC. | $76.71 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $44.98 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $38.25 | 2023 | Inpefa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.69 | 2023 | |
| Amarin Pharma, INC. | $19.53 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.09 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziyad Peer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.